Saama Launches AI Tool that Automates Data Quality Checks
Data quality co-pilot considered the first of its kind.
Saama, an artificial intelligence (AI) solutions provider, has introduced a data quality (DQ) co-pilot, a feature embedded directly into its Smart Data Quality (SDQ) tool, that quickly generates code for simple to complex, cross-domain data quality checks and tests them using generative artificial intelligence (GenAI). According to the company, the product has the potential to significantly accelerate clinical development by eliminating the need to manually program, test, and deploy data quality checks.
“Generative AI and its application in clinical data management is transforming our approach to the visualization and analysis of clinical trial data,” said Malaikannan Sankarasubbu, VP, AI Research, Saama. “The time and effort saved using Saama’s embedded DQ co-pilot is empowering clinical development by enabling faster trail setup and giving precious time back to data managers. This time can be used to support more studies and focus their talent on higher-value activities, all with the goal to get new treatments to patients more quickly.”
Reference: Saama Introduces Industry’s First Generative AI Tool to Automate Data Quality Checks. Saama. September 19, 2023. Accessed September 20, 2023. https://www.saama.com/news/saama-introduces-industrys-first-generative-ai-toolto-automate-data-quality-checks/
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
WCG Meets Enrollment 24 Months Early for Top 5 Pharma’s Decentralized Trial
October 31st 2024A sponsor needed to get their Phase II dermatology study enrollment back on track. The study was underway for 11 months across 32 sites globally with only 20 subjects enrolled to date. With WCG support, enrollment was concluded 24 months ahead of schedule.
